1.1 	A bill for an act
1.2 	relating to public safety; modifying the schedules of controlled substances;
1.3 	amending Minnesota Statutes 2016, section 152.02, subdivisions 2, 12.
1.4 	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.5 	Section 1. Minnesota Statutes 2016, section 152.02, subdivision 2, is amended to read:
1.6 		Subd. 2.Schedule I. (a) Schedule I consists of the substances listed in this subdivision.
1.7 	(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the 
1.8 	following substances, including their analogs, isomers, esters, ethers, salts, and salts of 
1.9 	isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers, 
1.10 	and salts is possible:
1.11 	(1) acetylmethadol;
1.12 	(2) allylprodine;
1.13 	(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl 
1.14 	acetate);
1.15 	(4) alphameprodine;
1.16 	(5) alphamethadol;
1.17 	(6) alpha-methylfentanyl benzethidine;
1.18 	(7) betacetylmethadol;
1.19 	(8) betameprodine;
1.20 	(9) betamethadol;
2.1 	(10) betaprodine;
2.2 	(11) clonitazene;
2.3 	(12) dextromoramide;
2.4 	(13) diampromide;
2.5 	(14) diethyliambutene;
2.6 	(15) difenoxin;
2.7 	(16) dimenoxadol;
2.8 	(17) dimepheptanol;
2.9 	(18) dimethyliambutene;
2.10 	(19) dioxaphetyl butyrate;
2.11 	(20) dipipanone;
2.12 	(21) ethylmethylthiambutene;
2.13 	(22) etonitazene;
2.14 	(23) etoxeridine;
2.15 	(24) furethidine;
2.16 	(25) hydroxypethidine;
2.17 	(26) ketobemidone;
2.18 	(27) levomoramide;
2.19 	(28) levophenacylmorphan;
2.20 	(29) 3-methylfentanyl;
2.21 	(30) acetyl-alpha-methylfentanyl;
2.22 	(31) alpha-methylthiofentanyl;
2.23 	(32) benzylfentanyl beta-hydroxyfentanyl;
2.24 	(33) beta-hydroxy-3-methylfentanyl;
2.25 	(34) 3-methylthiofentanyl;
2.26 	(35) thenylfentanyl;
2.27 	(36) thiofentanyl;
3.1 	(37) para-fluorofentanyl;
3.2 	(38) morpheridine;
3.3 	(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
3.4 	(40) noracymethadol;
3.5 	(41) norlevorphanol;
3.6 	(42) normethadone;
3.7 	(43) norpipanone;
3.8 	(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
3.9 	(45) phenadoxone;
3.10 	(46) phenampromide;
3.11 	(47) phenomorphan;
3.12 	(48) phenoperidine;
3.13 	(49) piritramide;
3.14 	(50) proheptazine;
3.15 	(51) properidine;
3.16 	(52) propiram;
3.17 	(53) racemoramide;
3.18 	(54) tilidine;
3.19 	(55) trimeperidine;
3.20 	(56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
3.21 	(57) 
3.22 	3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide(U47700); 
3.23 	and
3.24 	(58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl).
3.25 	(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers, 
3.26 	and salts of isomers, unless specifically excepted or unless listed in another schedule, 
3.27 	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
3.28 	(1) acetorphine;
4.1 	(2) acetyldihydrocodeine;
4.2 	(3) benzylmorphine;
4.3 	(4) codeine methylbromide;
4.4 	(5) codeine-n-oxide;
4.5 	(6) cyprenorphine;
4.6 	(7) desomorphine;
4.7 	(8) dihydromorphine;
4.8 	(9) drotebanol;
4.9 	(10) etorphine;
4.10 	(11) heroin;
4.11 	(12) hydromorphinol;
4.12 	(13) methyldesorphine;
4.13 	(14) methyldihydromorphine;
4.14 	(15) morphine methylbromide;
4.15 	(16) morphine methylsulfonate;
4.16 	(17) morphine-n-oxide;
4.17 	(18) myrophine;
4.18 	(19) nicocodeine;
4.19 	(20) nicomorphine;
4.20 	(21) normorphine;
4.21 	(22) pholcodine; and
4.22 	(23) thebacon.
4.23 	(d) Hallucinogens. Any material, compound, mixture or preparation which contains any 
4.24 	quantity of the following substances, their analogs, salts, isomers (whether optical, positional, 
4.25 	or geometric), and salts of isomers, unless specifically excepted or unless listed in another 
4.26 	schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is 
4.27 	possible:
4.28 	(1) methylenedioxy amphetamine;
5.1 	(2) methylenedioxymethamphetamine;
5.2 	(3) methylenedioxy-N-ethylamphetamine (MDEA);
5.3 	(4) n-hydroxy-methylenedioxyamphetamine;
5.4 	(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
5.5 	(6) 2,5-dimethoxyamphetamine (2,5-DMA);
5.6 	(7) 4-methoxyamphetamine;
5.7 	(8) 5-methoxy-3, 4-methylenedioxyamphetamine;
5.8 	(9) alpha-ethyltryptamine;
5.9 	(10) bufotenine;
5.10 	(11) diethyltryptamine;
5.11 	(12) dimethyltryptamine;
5.12 	(13) 3,4,5-trimethoxyamphetamine;
5.13 	(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
5.14 	(15) ibogaine;
5.15 	(16) lysergic acid diethylamide (LSD);
5.16 	(17) mescaline;
5.17 	(18) parahexyl;
5.18 	(19) N-ethyl-3-piperidyl benzilate;
5.19 	(20) N-methyl-3-piperidyl benzilate;
5.20 	(21) psilocybin;
5.21 	(22) psilocyn;
5.22 	(23) tenocyclidine (TPCP or TCP);
5.23 	(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
5.24 	(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
5.25 	(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
5.26 	(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
5.27 	(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
6.1 	(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
6.2 	(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
6.3 	(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
6.4 	(32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
6.5 	(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
6.6 	(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
6.7 	(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
6.8 	(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
6.9 	(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
6.10 	(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine 
6.11 	(2-CB-FLY);
6.12 	(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
6.13 	(40) alpha-methyltryptamine (AMT);
6.14 	(41) N,N-diisopropyltryptamine (DiPT);
6.15 	(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
6.16 	(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
6.17 	(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
6.18 	(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
6.19 	(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
6.20 	(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
6.21 	(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
6.22 	(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
6.23 	(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
6.24 	(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
6.25 	(52) ~~5-methoxy-N-methyl-N-propyltryptamine~~
6.26 	5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
6.27 	(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
6.28 	(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
7.1 	(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
7.2 	(56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
7.3 	(57) methoxetamine (MXE);
7.4 	(58) 5-iodo-2-aminoindane (5-IAI);
7.5 	(59) 5,6-methylenedioxy-2-aminoindane (MDAI);
7.6 	(60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
7.7 	(61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
7.8 	(62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
7.9 	(63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
7.10 	(64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
7.11 	(65) N,N-Dipropyltryptamine (DPT);
7.12 	(66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
7.13 	(67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
7.14 	(68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
7.15 	(69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
7.16 	(70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethylnorketamine, 
7.17 	ethketamine, NENK); ~~and~~
7.18 	(71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
7.19 	(72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
7.20 	(73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
7.21 	(e) Peyote. All parts of the plant presently classified botanically as Lophophora williamsii 
7.22 	Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant, 
7.23 	and every compound, manufacture, salts, derivative, mixture, or preparation of the plant, 
7.24 	its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not 
7.25 	apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian 
7.26 	Church, and members of the American Indian Church are exempt from registration. Any 
7.27 	person who manufactures peyote for or distributes peyote to the American Indian Church, 
7.28 	however, is required to obtain federal registration annually and to comply with all other 
7.29 	requirements of law.
8.1 	(f) Central nervous system depressants. Unless specifically excepted or unless listed in 
8.2 	another schedule, any material compound, mixture, or preparation which contains any 
8.3 	quantity of the following substances, their analogs, salts, isomers, and salts of isomers 
8.4 	whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
8.5 	(1) mecloqualone;
8.6 	(2) methaqualone;
8.7 	(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
8.8 	(4) flunitrazepam; and
8.9 	(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine, 
8.10 	methoxyketamine).
8.11 	(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any 
8.12 	material compound, mixture, or preparation which contains any quantity of the following 
8.13 	substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the 
8.14 	analogs, salts, isomers, and salts of isomers is possible:
8.15 	(1) aminorex;
8.16 	(2) cathinone;
8.17 	(3) fenethylline;
8.18 	(4) methcathinone;
8.19 	(5) methylaminorex;
8.20 	(6) N,N-dimethylamphetamine;
8.21 	(7) N-benzylpiperazine (BZP);
8.22 	(8) methylmethcathinone (mephedrone);
8.23 	(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
8.24 	(10) methoxymethcathinone (methedrone);
8.25 	(11) methylenedioxypyrovalerone (MDPV);
8.26 	(12) 3-fluoro-N-methylcathinone (3-FMC);
8.27 	(13) methylethcathinone (MEC);
8.28 	(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
8.29 	(15) dimethylmethcathinone (DMMC);
9.1 	(16) fluoroamphetamine;
9.2 	(17) fluoromethamphetamine;
9.3 	(18) α-methylaminobutyrophenone (MABP or buphedrone);
9.4 	(19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
9.5 	(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
9.6 	(21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or 
9.7 	naphyrone);
9.8 	(22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
9.9 	(23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
9.10 	(24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
9.11 	(25) 4-methyl-N-ethylcathinone (4-MEC);
9.12 	(26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
9.13 	(27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
9.14 	(28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone);
9.15 	(29) 4-fluoro-N-methylcathinone (4-FMC);
9.16 	(30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
9.17 	(31) alpha-pyrrolidinobutiophenone (α-PBP);
9.18 	(32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
9.19 	(33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
9.20 	(34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB); ~~and~~
9.21 	(35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
9.22 	(36) 4'-chloro-alpha-pyrrolidinopropiophenone (4-chloro-PPP);
9.23 	(37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB); 
9.24 	and
9.25 	(38) any other substance, except bupropion or compounds listed under a different 
9.26 	schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the 
9.27 	1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the 
9.28 	compound is further modified in any of the following ways:
10.1 	(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, 
10.2 	haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring 
10.3 	system by one or more other univalent substituents;
10.4 	(ii) by substitution at the 3-position with an acyclic alkyl substituent;
10.5 	(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or 
10.6 	methoxybenzyl groups; or
10.7 	(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
10.8 	(h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically 
10.9 	excepted or unless listed in another schedule, any natural or synthetic material, compound, 
10.10 	mixture, or preparation that contains any quantity of the following substances, their analogs, 
10.11 	isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence 
10.12 	of the isomers, esters, ethers, or salts is possible:
10.13 	(1) marijuana;
10.14 	(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, synthetic 
10.15 	equivalents of the substances contained in the cannabis plant or in the resinous extractives 
10.16 	of the plant, or synthetic substances with similar chemical structure and pharmacological 
10.17 	activity to those substances contained in the plant or resinous extract, including, but not 
10.18 	limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4 
10.19 	cis or trans tetrahydrocannabinol;
10.20 	(3) synthetic cannabinoids, including the following substances:
10.21 	(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole 
10.22 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
10.23 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
10.24 	2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any 
10.25 	extent and whether or not substituted in the naphthyl ring to any extent. Examples of 
10.26 	naphthoylindoles include, but are not limited to:
10.27 	(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
10.28 	(B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);
10.29 	(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
10.30 	(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
10.31 	(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
11.1 	(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
11.2 	(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
11.3 	(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
11.4 	(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
11.5 	(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
11.6 	(ii) Napthylmethylindoles, which are any compounds containing a 
11.7 	1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the 
11.8 	indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
11.9 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further 
11.10 	substituted in the indole ring to any extent and whether or not substituted in the naphthyl 
11.11 	ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
11.12 	(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
11.13 	(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).
11.14 	(iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole 
11.15 	structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, 
11.16 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
11.17 	2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any 
11.18 	extent, whether or not substituted in the naphthyl ring to any extent. Examples of 
11.19 	naphthoylpyrroles include, but are not limited to, 
11.20 	(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
11.21 	(iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene 
11.22 	structure with substitution at the 3-position of the indene ring by an allkyl, haloalkyl, alkenyl, 
11.23 	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
11.24 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any 
11.25 	extent, whether or not substituted in the naphthyl ring to any extent. Examples of 
11.26 	naphthylemethylindenes include, but are not limited to, 
11.27 	E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
11.28 	(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole 
11.29 	structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, 
11.30 	alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
11.31 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any 
11.32 	extent, whether or not substituted in the phenyl ring to any extent. Examples of 
11.33 	phenylacetylindoles include, but are not limited to:
12.1 	(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
12.2 	(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
12.3 	(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
12.4 	(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
12.5 	(vi) Cyclohexylphenols, which are compounds containing a 
12.6 	2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic 
12.7 	ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 
12.8 	1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted 
12.9 	in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not 
12.10 	limited to:
12.11 	(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
12.12 	(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol 
12.13 	(Cannabicyclohexanol or CP 47,497 C8 homologue);
12.14 	(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] 
12.15 	-phenol (CP 55,940).
12.16 	(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure 
12.17 	with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, 
12.18 	cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 
12.19 	2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any 
12.20 	extent and whether or not substituted in the phenyl ring to any extent. Examples of 
12.21 	benzoylindoles include, but are not limited to:
12.22 	(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
12.23 	(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
12.24 	(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN 
12.25 	48,098 or Pravadoline).
12.26 	(viii) Others specifically named:
12.27 	(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
12.28 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
12.29 	(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) 
12.30 	-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
13.1 	(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] 
13.2 	-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
13.3 	(D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
13.4 	(E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 
13.5 	(XLR-11);
13.6 	(F) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide 
13.7 	(AKB-48(APINACA));
13.8 	(G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 
13.9 	(5-Fluoro-AKB-48);
13.10 	(H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
13.11 	(I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
13.12 	(J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole- 3-carboxamide 
13.13 	(AB-PINACA);
13.14 	(K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]- 
13.15 	1H-indazole-3-carboxamide (AB-FUBINACA);
13.16 	(L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H- 
13.17 	indazole-3-carboxamide(AB-CHMINACA);
13.18 	(M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3- methylbutanoate 
13.19 	(5-fluoro-AMB);
13.20 	(N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
13.21 	(O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone) 
13.22 	(FUBIMINA);
13.23 	(P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo 
13.24 	[2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
13.25 	(Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl) 
13.26 	-1H-indole-3-carboxamide (5-fluoro-ABICA);
13.27 	(R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) 
13.28 	-1H-indole-3-carboxamide;
13.29 	(S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl) 
13.30 	-1H-indazole-3-carboxamide;
14.1 	(T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;
14.2 	(U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1 
14.3 	H-indazole-3-carboxamide (MAB-CHMINACA);
14.4 	(V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide 
14.5 	(ADB-PINACA);
14.6 	(W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
14.7 	(X) 
14.8 	N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-3-carboxamide. 
14.9 	(APP-CHMINACA); ~~and~~
14.10 	(Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
14.11 	(Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
14.12 	(i) A controlled substance analog, to the extent that it is implicitly or explicitly intended 
14.13 	for human consumption.

14.14 	Sec. 2. Minnesota Statutes 2016, section 152.02, subdivision 12, is amended to read:
14.15 		Subd. 12.Coordination of controlled substance regulation with federal law and 
14.16 	state statute. If any substance is designated, rescheduled, or deleted as a controlled substance 
14.17 	under federal law ~~and notice thereof is given to the state Board of Pharmacy, the state Board~~ 
14.18 	~~of Pharmacy shall similarly control the substance under this chapter, after the expiration of~~ 
14.19 	~~30 days from publication in the Federal Register of a final order designating a substance as~~ 
14.20 	~~a controlled substance or rescheduling or deleting a substance. Such order shall be filed~~ 
14.21 	~~with the secretary of state. If within that 30-day period, the state Board of Pharmacy objects~~ 
14.22 	~~to inclusion, rescheduling, or deletion, it shall publish the reasons for objection and afford~~ 
14.23 	~~all interested parties an opportunity to be heard. At the conclusion of the hearing, the state~~ 
14.24 	~~Board of Pharmacy shall publish its decision, which shall be subject to the provisions of~~ 
14.25 	~~chapter 14~~, the substance shall be deemed to be similarly designated, rescheduled, or deleted 
14.26 	under this section until the legislature enacts legislation or the board engages in rulemaking 
14.27 	to otherwise schedule the drug.
14.28 	In exercising the authority granted by this chapter, the state Board of Pharmacy shall be 
14.29 	subject to the provisions of chapter 14.
14.30 	The state Board of Pharmacy shall annually submit a report to the legislature on or before 
14.31 	December 1 that specifies what changes the board made to the controlled substance schedules 
14.32 	maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, in the preceding 
15.1 	12 months. The report must include specific recommendations for amending the controlled 
15.2 	substance schedules contained in subdivisions 2 to 6, so that they conform with the controlled 
15.3 	substance schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 
15.4 	6800.4250.